Georgia's Online Cancer Information Center

Primary Peritoneal Cancer Clinical Trials in Georgia

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Cancer Type = Primary Peritoneal Cancer
Cancer Type = Primary Peritoneal Cancer
There are currently 9 active Primary Peritoneal Cancer clinical trials in Georgia.
1.
NCORP Trial
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Cancer Type
Bile Duct Cancer, Bladder Cancer, Breast Cancer, Colon/Rectal Cancer, Esophogeal Cancer, Gynecologic Cancers, Head and Neck Cancer, Hematopoietic Malignancies, Liver Cancer / Hepatoblastoma, Lung Cancer, Melanoma, Ovarian Cancer, Primary Peritoneal Cancer, Stomach/ Gastric Cancer
NCT ID
NCT03329950
Protocol IDs
CDX1140-01
NCI-2018-00959
Treatment Sites (2)
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
2.
A Study of RGX-104 in Patients With Advanced Solid Malignancies and Lymphoma
Cancer Type
Gynecologic Cancers, Lung Cancer, Lymphoma, Neuroendocrine Tumor, Ovarian Cancer, Primary Peritoneal Cancer, Solid Tumor
NCT ID
NCT02922764
Protocol IDs
RGX-104-001
NCI-2017-00226
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
3.
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
Cancer Type
Cervical Cancer, Gynecologic Cancers, Head and Neck Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Melanoma, Ovarian Cancer, Pancreatic Cancer, Penile Cancer, Primary Peritoneal Cancer
NCT ID
NCT03849469
Protocol IDs
XmAb22841-01
NCI-2019-02498
DUET-4
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
4.
First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b
Cancer Type
Gynecologic Cancers, Lung Cancer, Ovarian Cancer, Primary Peritoneal Cancer, Solid Tumor
NCT ID
NCT03319628
Protocol IDs
XMT-1536-1
NCI-2018-00402
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
5.
NCORP Trial
Letrozole with or without Paclitaxel and Carboplatin in Treating Patients with Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCT ID
NCT04095364
Protocol IDs
NRG-GY019
NRG-GY019
NCI-2019-01460
Treatment Sites (2)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
6.
Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors
Cancer Type
Gynecologic Cancers, Liver Cancer / Hepatoblastoma, Lung Cancer, Ovarian Cancer, Primary Peritoneal Cancer
NCT ID
NCT03836352
Protocol IDs
P1719-SUR-Z11
NCI-2019-03013
Keynote 903
Treatment Sites (2)
Emory Clinic
Atlanta
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
7.
Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
Cancer Type
Breast Cancer, Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Prostate Cancer , Solid Tumor, Unknown Primary
NCT ID
NCT04726332
Protocol IDs
XL102-101
NCI-2021-03620
8.
Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer
NCT ID
NCT04034927
Protocol IDs
NRG-GY021
NRG-GY021
NCI-2019-04829
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
9.
NCORP Trial
Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer
NCT ID
NCT02502266
Protocol IDs
NRG-GY005
NCI-2015-00651
Treatment Sites (24)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Atlanta Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Georgia Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
University Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
WellStar Cobb Hospital
Austell
770-793-5980
WellStar Kennestone Hospital
Marietta
770-793-5980
WellStar North Fulton Hospital
Roswell
Micah Brown
770-751-2556
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a statewide nonprofit that leverages partnerships and innovation to attract more clinical trials, increase research, and promote education and early detection to improve cancer care for Georgians in rural, urban, and suburban communities across the state.